Stoke Therapeutics price target lowered to $14 from $18 at Cantor Fitzgerald

Cantor Fitzgerald analyst Charles Duncan lowered the firm’s price target on Stoke Therapeutics to $14 from $18 and keeps an Overweight rating on the shares following the Q2 results. While the firm believes Stoke is underappreciated despite having recently established clinical PoC for STK-001, a distinct precision-medicine therapeutic approach that may prove more-than-additive to current seizure-reduction-driven standard of care for Dravet patients, Cantor acknowledges the current risk-off market and the need for additional clinical data on ‘001 to affirm the thesis, the analyst tells investors in a research note.